Calamos Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Calamos Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$11.6M	–	1031
2023 Q3	$11.6M	Sell	100,000 -128,495	-56%	-$13.8M	0.06%	359
2023 Q2	$23.5M	Hold	228,495	–	–	0.12%	225
2023 Q1	$24.9M	Buy	228,495 +171,937	+304%	+$19M	0.12%	212
2022 Q4	$6.44M	Buy	+56,558	New	+$4.7M	0.03%	596
2022 Q1	–	Sell	-56,567	Closed	-$6.1M	–	1256
2021 Q4	$6.1M	Sell	56,567 -22,849	-29%	-$2.49M	0.02%	637
2021 Q3	$8.7M	Buy	79,416 +25,738	+48%	+$2.67M	0.04%	467
2021 Q2	$5.03M	Buy	53,678 +34,564	+181%	+$3.18M	0.02%	558
2021 Q1	$1.76M	Sell	19,114 -712	-4%	-$60.1K	0.01%	711
2020 Q4	$1.45M	Buy	19,826 +2,075	+12%	+$154K	0.01%	660
2020 Q3	$1.38M	Buy	17,751 +6,038	+52%	+$415K	0.01%	621
2020 Q2	$651K	Buy	+11,713	New	+$501K	﹤0.01%	670
2020 Q1	–	Sell	-13,400	Closed	-$485K	–	837
2019 Q4	$485K	Hold	13,400	–	–	﹤0.01%	715
2019 Q3	$365K	Hold	13,400	–	–	﹤0.01%	719
2019 Q2	$322K	Hold	13,400	–	–	﹤0.01%	716
2019 Q1	$354K	Buy	13,400 +400	+3%	+$9.48K	﹤0.01%	627
2018 Q4	$254K	Buy	+13,000	New	+$255K	﹤0.01%	638

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Calamos Advisors's HZNP Position: Q4 2023 in Review

Calamos Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 100,000 shares — an estimated $11.6M sold.

Calamos Advisors first reported a position in HZNP in Q4 2018 and held it in 16 quarters. The position peaked at $24.9M in Q1 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Calamos Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Calamos Advisors sold 100,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $11.6M.
Calamos Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 16 quarters.
Calamos Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $24.9M in Q1 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Calamos Advisors's 13F filing for Q4 2023, filed 31 Jan 2024.